Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study
Flibanserin (FLB) was approved by FDA for the treatment of pre-menopausal female hypoactive sexual desire disorder (HSDD). FLB suffers from low oral bioavailability (33%) which might be due to hepatic first-pass metabolism in addition to its poor aqueous solubility. The sublingual route could be a p...
Zapisane w:
| Główni autorzy: | , |
|---|---|
| Format: | Książka |
| Wydane: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
| Hasła przedmiotowe: | |
| Dostęp online: | Connect to this object online. |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sygnatura: |
A1234.567 |
|---|---|
| Egzemplarz 1 | Dostępne |